IL318533A - Nlrp3 inflammasome inhibitors - Google Patents
Nlrp3 inflammasome inhibitorsInfo
- Publication number
- IL318533A IL318533A IL318533A IL31853325A IL318533A IL 318533 A IL318533 A IL 318533A IL 318533 A IL318533 A IL 318533A IL 31853325 A IL31853325 A IL 31853325A IL 318533 A IL318533 A IL 318533A
- Authority
- IL
- Israel
- Prior art keywords
- nlrp3 inflammasome
- inflammasome inhibitors
- inhibitors
- nlrp3
- inflammasome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370300P | 2022-08-03 | 2022-08-03 | |
| CN2023097282 | 2023-05-30 | ||
| PCT/IB2023/057819 WO2024028782A1 (en) | 2022-08-03 | 2023-08-02 | Nlrp3 inflammasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318533A true IL318533A (en) | 2025-03-01 |
Family
ID=87580191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318533A IL318533A (en) | 2022-08-03 | 2023-08-02 | Nlrp3 inflammasome inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240067627A1 (en) |
| EP (1) | EP4565326A1 (en) |
| JP (1) | JP7881051B2 (en) |
| KR (1) | KR20250043519A (en) |
| CN (2) | CN119677725A (en) |
| AR (1) | AR130094A1 (en) |
| AU (2) | AU2023318764B2 (en) |
| CA (1) | CA3262660A1 (en) |
| CL (1) | CL2025000285A1 (en) |
| CO (1) | CO2025002057A2 (en) |
| CR (1) | CR20250063A (en) |
| DO (1) | DOP2025000013A (en) |
| IL (1) | IL318533A (en) |
| JO (1) | JOP20250023A1 (en) |
| MA (1) | MA71689A (en) |
| MX (1) | MX2025001273A (en) |
| PE (1) | PE20251255A1 (en) |
| TW (1) | TW202406550A (en) |
| UY (1) | UY40374A (en) |
| WO (1) | WO2024028782A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| TW202545527A (en) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3 and glp-1a combination therapies |
| WO2026057634A1 (en) * | 2024-09-11 | 2026-03-19 | Sanofi | Crystalline form of a pyridazine nlrp3 inhibitor |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2510997A1 (en) | 1981-08-10 | 1983-02-11 | Sanofi Sa | NOVEL DERIVATIVES OF METHYL-4-PHENYL-6-PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND ACTIVE MEDICINES ON CENTRAL NERVOUS SYSTEM CONTAINING THE SAME |
| PT93060B (en) | 1989-02-07 | 1995-12-29 | Sanofi Sa | METHOD FOR OBTAINING PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2663326B2 (en) | 1989-11-17 | 1992-10-16 | Sanofi Sa | PYRIDAZINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
| FR2676444B1 (en) | 1991-05-16 | 1995-03-10 | Sanofi Elf | NOVEL AMINO-3 PYRIDAZINE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. |
| US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| EP1745039A4 (en) | 2004-05-08 | 2009-07-22 | Neurogen Corp | 3-aryl-5,6-disubstituted pyridazines |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2008058064A1 (en) | 2006-11-07 | 2008-05-15 | Lexicon Pharmaceuticals, Inc. | Amine-linked multicyclic compounds as inhibitors of the proline transporter |
| GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| KR20120087950A (en) | 2009-10-20 | 2012-08-07 | 노파르티스 아게 | Glycoside derivative and uses thereof |
| ES2622138T3 (en) | 2010-06-23 | 2017-07-05 | Hanmi Science Co., Ltd. | New condensed pyrimidine derivatives for the inhibition of tyrosine kinase activity |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| PH12013500246A1 (en) | 2010-08-10 | 2019-10-11 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| CU24152B1 (en) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| UA111756C2 (en) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS |
| BR112014012727B1 (en) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | 6-AMINO-9-[(3R)-1-(2-BUTINOYL)-3-PYRROLIDINYL]-7-(4-PHENOXYPHENYL)-7,9-DIHYDRO-8H-PURI-8-ONE E PHARMACEUTICAL COMPOSITION |
| EP2858500A4 (en) | 2012-06-08 | 2016-04-06 | Biogen Ma Inc | INHIBITORS OF BRUTON TYROSINE KINASE |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| SMT201900344T1 (en) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Pyrazolopyrimidine compounds as kinase inhibitors |
| WO2014085474A1 (en) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| UY35368A (en) | 2013-03-08 | 2014-10-31 | Irm Llc | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE |
| JO3377B1 (en) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | Pyridinyl and fused pyridinyl triazolone derivatives |
| PL2989106T3 (en) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| SG11201603026PA (en) | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| TN2016000127A1 (en) | 2013-12-20 | 2017-10-06 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors. |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| UA122479C2 (en) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Isolated ANTIBODY MOLECULE BINDS TO HUMAN PROGRAMMED DEATH-1 (PD-1) PROTEIN |
| PL3099717T3 (en) | 2014-01-31 | 2019-10-31 | Novartis Ag | Antibody molecules to tim-3 and uses thereof |
| EA201691765A1 (en) | 2014-03-14 | 2016-12-30 | Новартис Аг | ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS |
| HRP20241236T1 (en) | 2014-05-13 | 2024-12-06 | Novartis Ag | COMPOUNDS AND PREPARATIONS FOR INDUCING CHONDROGENESIS |
| CN103965169A (en) | 2014-05-30 | 2014-08-06 | 彭正中 | Compound as well as preparation method and application of compound |
| WO2016022626A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| MX393057B (en) | 2014-10-24 | 2025-03-24 | Bristol Myers Squibb Co | INDOL CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS. |
| CN107427468B (en) | 2014-12-24 | 2022-02-25 | 普林斯匹亚生物制药公司 | Site-Specific Administration of BTK Inhibitors |
| ES2907461T3 (en) | 2015-01-20 | 2022-04-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and methods of use thereof |
| US20180008629A1 (en) | 2015-01-29 | 2018-01-11 | Yale University | Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| JP6929792B2 (en) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | Sulfonylureas and related compounds and their use |
| MA41598A (en) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | PYRIDAZINE THERAPEUTIC COMPOUNDS AND THEIR USES |
| EP3912979B1 (en) | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| MA42510A (en) | 2015-06-10 | 2018-06-06 | Biogen Ma Inc | FORMS AND COMPOSITIONS OF BIARYL INHIBITORS OF BRUTON TYROSINE KINASE |
| EP3359159B1 (en) | 2015-10-09 | 2023-06-07 | ACEA Therapeutics, Inc. | Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same |
| TW202510883A (en) | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| ES2875384T3 (en) | 2016-01-05 | 2021-11-10 | Jiangsu Hengrui Medicine Co | Crystal form of BTK kinase inhibitor and method of its preparation |
| CN109071524A (en) | 2016-01-15 | 2018-12-21 | 布里格姆及妇女医院股份有限公司 | Pyridyl derivatives as EAAT2 activator |
| KR101865120B1 (en) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | Wireless positioning method based on test node and apparatus thereof |
| IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| TWI674261B (en) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 modulators |
| CN111372611A (en) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | Methods for modifying RNA splicing |
| CN110914256A (en) | 2017-07-07 | 2020-03-24 | 英夫拉索姆有限公司 | Novel sulfonamide carboxamide compounds |
| ES3002968T3 (en) | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| MX2020001425A (en) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing. |
| MX2020001776A (en) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP<sub>3</sub> INHIBITORS. |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
| BR112020007058A2 (en) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
| CN111315733A (en) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | Novel sulfonamide carboxamide compounds |
| BR112020019373A2 (en) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | COMPOUNDS FOR THE TREATMENT OF HUTINGTON'S DISEASE |
| JP2021521200A (en) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | Compounds for the treatment of cancer |
| SG11202104495YA (en) | 2018-04-26 | 2021-05-28 | Aurigene Discovery Tech Ltd | Pyridazine derivatives as smarca2/4 degraders |
| AR119731A1 (en) | 2019-05-17 | 2022-01-05 | Novartis Ag | NLRP3 INFLAMASOME INHIBITORS |
| CN115279739B (en) * | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | Substituted pyridazine compounds |
| US20230348437A1 (en) * | 2020-07-02 | 2023-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| TW202231281A (en) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | A class of pyridazine containing compounds and medicinal uses thereof |
| EP4289823A4 (en) * | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
-
2023
- 2023-07-27 UY UY0001040374A patent/UY40374A/en unknown
- 2023-08-01 US US18/363,207 patent/US20240067627A1/en active Pending
- 2023-08-01 TW TW112128876A patent/TW202406550A/en unknown
- 2023-08-01 AR ARP230102029A patent/AR130094A1/en unknown
- 2023-08-02 IL IL318533A patent/IL318533A/en unknown
- 2023-08-02 PE PE2025000269A patent/PE20251255A1/en unknown
- 2023-08-02 KR KR1020257006563A patent/KR20250043519A/en active Pending
- 2023-08-02 CN CN202380056099.4A patent/CN119677725A/en active Pending
- 2023-08-02 CR CR20250063A patent/CR20250063A/en unknown
- 2023-08-02 JP JP2025505788A patent/JP7881051B2/en active Active
- 2023-08-02 WO PCT/IB2023/057819 patent/WO2024028782A1/en not_active Ceased
- 2023-08-02 EP EP23755486.0A patent/EP4565326A1/en active Pending
- 2023-08-02 CA CA3262660A patent/CA3262660A1/en active Pending
- 2023-08-02 CN CN202610038086.XA patent/CN121873039A/en active Pending
- 2023-08-02 AU AU2023318764A patent/AU2023318764B2/en active Active
- 2023-08-02 MA MA71689A patent/MA71689A/en unknown
-
2024
- 2024-10-16 US US18/917,653 patent/US12378222B2/en active Active
-
2025
- 2025-01-29 DO DO2025000013A patent/DOP2025000013A/en unknown
- 2025-01-30 JO JOJO/P/2025/0023A patent/JOP20250023A1/en unknown
- 2025-01-30 CL CL2025000285A patent/CL2025000285A1/en unknown
- 2025-01-30 MX MX2025001273A patent/MX2025001273A/en unknown
- 2025-02-25 CO CONC2025/0002057A patent/CO2025002057A2/en unknown
-
2026
- 2026-06-30 AU AU2026205161A patent/AU2026205161A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025000285A1 (en) | 2025-06-13 |
| UY40374A (en) | 2024-02-15 |
| AU2023318764B2 (en) | 2026-04-23 |
| TW202406550A (en) | 2024-02-16 |
| CA3262660A1 (en) | 2024-02-08 |
| KR20250043519A (en) | 2025-03-28 |
| WO2024028782A1 (en) | 2024-02-08 |
| AU2023318764A1 (en) | 2025-01-09 |
| CR20250063A (en) | 2025-03-27 |
| AU2026205161A1 (en) | 2026-07-16 |
| PE20251255A1 (en) | 2025-05-06 |
| DOP2025000013A (en) | 2025-02-28 |
| MX2025001273A (en) | 2025-03-07 |
| JP2025525866A (en) | 2025-08-07 |
| US20250034114A1 (en) | 2025-01-30 |
| US12378222B2 (en) | 2025-08-05 |
| MA71689A (en) | 2025-05-30 |
| CO2025002057A2 (en) | 2025-03-06 |
| US20240067627A1 (en) | 2024-02-29 |
| CN121873039A (en) | 2026-04-17 |
| CN119677725A (en) | 2025-03-21 |
| JOP20250023A1 (en) | 2025-01-30 |
| EP4565326A1 (en) | 2025-06-11 |
| JP7881051B2 (en) | 2026-06-26 |
| AR130094A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4363406T (en) | Nlrp3 inflammasome inhibitors | |
| IL318258A (en) | Novel nlrp3 inflammasome inhibitors | |
| IL287042A (en) | Nlrp3 inflammasome inhibitors | |
| SI4337652T1 (en) | Nlrp3 inhibitors | |
| IL306022A (en) | Inhibitors of nlrp3 inflammasome | |
| IL280336A (en) | Nlrp3 inflammasome inhibitors | |
| CA3262660A1 (en) | Nlrp3 inflammasome inhibitors | |
| IL315027A (en) | NLRP3 inhibitors | |
| IL319011A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| IL314049A (en) | Parp7 inhibitors | |
| IL319009A (en) | Triazinone derivatives as nlrp3 inhibitors | |
| IL308071A (en) | Process for the preparation of nlrp3 inhibitors | |
| EP4251630A4 (en) | NLRP3 INFLAMMASOME INHIBITORS SULFONYLUREA | |
| EP4293018A4 (en) | Compound serving as nlrp3 inhibitor | |
| PT4337652T (en) | Nlrp3 inhibitors | |
| HK40122493A (en) | Nlrp3 inflammasome inhibitors | |
| HK40128873A (en) | Novel nlrp3 inflammasome inhibitors | |
| HK40099180A (en) | Inhibitors of nlrp3 inflammasome | |
| HK40122649A (en) | Nlrp3 inhibitors | |
| HK40061653A (en) | Nlrp3 inflammasome inhibitors | |
| IL326491A (en) | NLRP3 inflammasome inhibitor and its use | |
| CA3286388A1 (en) | Nlrp3 inflammasome inhibitors and uses thereof | |
| HK40109676A (en) | Inhibitors of nlrp3 | |
| HK40117000A (en) | N-oxide inhibitors of nlrp3 inflammasome | |
| CA3280638A1 (en) | Inhibitors of nlrp3 |